SHINE Technologies has entered a supply agreement with C-Ray Therapeutics, a global radiopharmaceutical CRDMO, the company announced recently.

According to a release, C-Ray will supply SHINE’s n.c.a. Lu-177 to Chinese radiopharmaceutical developers, biotechnology companies and healthcare institutions.

“We are pleased to partner with C-Ray,” SHINE Technologies Founder and CEO Greg Piefer said in a statement. “This collaboration reflects SHINE’s ability to serve growing demand for n.c.a. Lu-177 in China while maintaining strong supply for customers in the U.S. and other global markets. By combining C-Ray’s integrated development and manufacturing platform with our large-scale isotope production, we can help advance pipeline innovation and expand patient access to life-saving targeted radioligand therapies.”

Under the terms of the agreement, SHINE’s Cassiopeia facility, one of North America’s largest n.c.a. Lu-177 production sites, will supply C-Ray.